ADC Therapeutics SA(ADCT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADCT ADC Therapeutics SA

交易中 08-13 11:09:34 EDT

1.10

-0.13

-10.58%

最高1.10	最低0.9393	成交量150.62万
今开1.07	昨收1.23	日振幅13.07%
总市值1.40亿	流通市值1.08亿	总股本1.27亿
成交额154.24万	换手率1.54%	流通股本9,777万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADCT","market":"US","secType":"STK","nameCN":"ADC Therapeutics SA","latestPrice":1.0999,"timestamp":1786633765788,"preClose":1.23,"halted":0,"volume":1506151,"delay":0,"changeRate":-0.10577235772357714,"floatShares":97770400,"shares":127044400,"eps":-1.0770324,"marketStatus":"交易中","change":-0.1301,"latestTime":"08-13 11:09:34 EDT","open":1.07,"high":1.1,"low":0.9393,"amount":1542352.845436,"amplitude":0.13065,"askPrice":1.1,"askSize":112,"bidPrice":1.09,"bidSize":653,"shortable":0,"etf":0,"ttmEps":-1.0770324,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1786651200000},"marketStatusCode":2,"adr":0,"listingDate":1589515200000,"exchange":"NYSE","adjPreClose":1.23,"preHourTrading":{"tag":"盘前","latestPrice":1.06,"preClose":1.23,"latestTime":"09:29 EDT","volume":60009,"amount":68778.175179,"timestamp":1786627798607,"change":-0.17,"changeRate":-0.138211,"amplitude":0.170732},"postHourTrading":{"tag":"盘后","latestPrice":1.2283,"preClose":1.23,"latestTime":"19:40 EDT","volume":11201,"amount":13769.2326,"timestamp":1786578022302,"change":-0.0017,"changeRate":-0.001382,"amplitude":0.02439},"volumeRatio":9.614535,"impliedVol":0.2391,"impliedVolPercentile":0.2669},"requestUrl":"/m/hq/s/ADCT","defaultTab":"news","newsList":[{"id":"1186187715","title":"ADC Therapeutics第二季度运营亏损达2541.4万美元，超出市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1186187715","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186187715?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:48","pubTimestamp":1786621728,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA（ADCT）于8月13日公布了第二季度财务数据。数据显示，公司当季运营亏损为2541.4万美元，而此前IBES（Institutional Brokers' Estimate System，机构经纪商预估系统）的市场预期仅为2440万美元，实际亏损幅度超出预期。与此同时，该公司第二季度净亏损为1656.5万美元，相较之下，市场普遍预估的净亏损额为3400万美元，实际亏损水平显著低于预期。这一结果反映出公司在运营成本控制与财务表现上存在一定的不确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADCT","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177012930","title":"ADC Therapeutics计划裁员以削减成本 预计每年可节省约1000万美元开支","url":"https://stock-news.laohu8.com/highlight/detail?id=1177012930","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177012930?lang=zh_cn&edition=full","pubTime":"2026-06-24 19:33","pubTimestamp":1782300814,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA宣布了一项旨在优化运营效率的重组计划，其中包含对员工队伍的战略性调整。这项举措预计将为公司带来显著的年度成本节约，金额大约在1000万美元左右。\n通过精简组织架构，公司旨在更有效地配置资源，集中力量推进核心研发管线及关键业务优先事项。这一调整反映了管理层在复杂市场环境中，为提升财务韧性和长期竞争力所采取的积极行动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADCT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167863706","title":"ADC Therapeutics宣布战略重组，以支持Zynlonta®增长机遇与监管重点","url":"https://stock-news.laohu8.com/highlight/detail?id=1167863706","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167863706?lang=zh_cn&edition=full","pubTime":"2026-06-24 19:30","pubTimestamp":1782300621,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA宣布实施一项战略重组计划，旨在全力支持其核心产品Zynlonta®的增长机遇，并优先推进相关监管事务。此次重组将优化公司资源配置，聚焦于关键战略领域，以加速Zynlonta®的商业化进程并应对未来的监管挑战。公司表示，这一举措是为了更好地适应市场动态，强化其产品管线，并确保长期可持续发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADCT","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150050319","title":"ADC Therapeutics宣布Zynlonta联合利妥昔单抗在LOTIS-5研究中达到无进展生存期主要终点统计学意义","url":"https://stock-news.laohu8.com/highlight/detail?id=1150050319","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150050319?lang=zh_cn&edition=full","pubTime":"2026-06-04 04:11","pubTimestamp":1780517477,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA公布，其药物Zynlonta与利妥昔单抗联合疗法，在关键临床研究LOTIS-5中，成功达到了无进展生存期这一主要终点的统计学显著性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADCT","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138369597","title":"ADC Therapeutics公布Lotis-5三期确证性临床试验结果：Zynlonta®联合利妥昔单抗治疗复发或难治性弥漫大B细胞淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1138369597","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138369597?lang=zh_cn&edition=full","pubTime":"2026-06-04 04:05","pubTimestamp":1780517121,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA 公布了其关键性Lotis-5三期确证临床试验的数据。该研究旨在评估Zynlonta与利妥昔单抗联合疗法，用于治疗复发或难治性弥漫大B细胞淋巴瘤患者。此次三期试验的数据，将为Zynlonta在此适应症上的应用前景提供关键依据。Zynlonta是一种靶向CD19的抗体偶联药物。Lotis-5试验的结果，预计将影响未来的治疗格局与监管审评路径。公司此次信息发布，聚焦于临床数据本身。投资者与行业观察者正密切关注这些结果，以评估其对该药物商业潜力及ADC Therapeutics未来发展的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","ADCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151475343","title":"ADC Therapeutics SA公布截至2026年3月31日现金及等价物达2.31亿美元 资金可支撑至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=1151475343","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151475343?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:35","pubTimestamp":1777894518,"startTime":"0","endTime":"0","summary":"生物制药企业ADC Therapeutics SA近日披露最新财务数据，截至2026年3月31日，公司持有的现金及现金等价物规模达2.31亿美元。根据当前资金消耗速率测算，该资金储备预计可维持公司运营至2028年。在生物科技行业融资环境充满挑战的背景下，ADC Therapeutics SA凭借稳健的财务状况展现出差异化优势。公司管理层表示，现有资金将优先用于加速关键临床项目，同时探索商业合作机会以最大化资产价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADCT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174289891","title":"ADC Therapeutics SA：Lotis-5三期试验顶线数据预计2026年第二季度公布；Lotis-5及Lotis-7完整数据将于年底前揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1174289891","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174289891?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:35","pubTimestamp":1777894514,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA宣布，其备受关注的Lotis-5三期临床试验的顶线数据预计将在2026年第二季度获得。此外，公司计划在2026年年底前公布Lotis-5研究的完整数据集，以及Lotis-7试验的相关数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","ADCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176599485","title":"ADC Therapeutics SA：部分股东或不时出售至多9,834,776股普通股——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1176599485","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176599485?lang=zh_cn&edition=full","pubTime":"2026-03-11 05:11","pubTimestamp":1773177073,"startTime":"0","endTime":"0","summary":"根据最新提交至美国证券交易委员会（SEC）的文件显示，生物制药公司ADC Therapeutics SA的部分持股股东可能在未来一段时间内，陆续出售其持有的公司普通股，总量最高可达9,834,776股。\n此类由现有股东发起的二级市场发售，通常不会为公司带来新的融资。市场参与者将密切关注后续的实际出售情况，以评估其对股价的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADCT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110287836","title":"ADC Therapeutics SA公布2025年第四季度及全年财务业绩并更新运营进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1110287836","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110287836?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:31","pubTimestamp":1773142281,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA（简称：ADCT）近日正式披露了2025财年第四季度及全年的财务报告，同时向市场通报了公司最新的运营动态。此次公布的数据全面反映了公司在过去一年中的财务健康状况与业务推进情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","ADCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109084963","title":"ADC Therapeutics SA：若发生控制权变更，收购方将继续支付特许权使用费直至达到原定上限","url":"https://stock-news.laohu8.com/highlight/detail?id=1109084963","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109084963?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:19","pubTimestamp":1771849168,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA宣布，在控制权变更的情况下，收购方将继续向医疗保健特许权公司支付特许权使用费，直至达到原始约定的上限金额。这一安排确保了特许权收益的持续性，不受公司所有权结构变化的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADCT","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191972270","title":"ADC Therapeutics SA预计2027年起实现显著增长，美国市场潜在年收入峰值或达6亿至10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191972270","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191972270?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:17","pubTimestamp":1771849037,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA（简称ADCT）近日发布业绩展望，预计公司将从2027年开始进入实质性增长阶段。据分析，其在美国市场的潜在年收入峰值有望达到6亿美元至10亿美元区间。\n这一乐观预期基于公司核心产品管线的商业化进展及市场扩张策略。随着创新疗法逐步获得监管批准并扩大适应症，ADC Therapeutics有望在肿瘤治疗领域占据重要市场份额。\n公司管理层强调，这一增长轨迹依赖于临床开发计划的顺利执行以及市场渗透策略的有效实施。若各项进展符合预期，2027年后公司财务表现将迎来显著提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADCT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119850242","title":"ADC Therapeutics SA获医疗保健特许权公司授予认股权证 可购买约980万股普通股 行权价每股3.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119850242","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119850242?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:17","pubTimestamp":1771849034,"startTime":"0","endTime":"0","summary":"医疗保健特许权投资公司向ADC Therapeutics SA授予了约980万股普通股的认购权证。根据协议条款，每份权证的行权价格确定为每股3.81美元。此次权证授予将为ADC Therapeutics SA带来潜在的资本注入，同时为投资者提供了未来以固定价格购入该公司普通股的权利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADCT","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518099672","title":"Adc Therapeutics Sa盘中异动 股价大跌5.16%报1.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518099672","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518099672?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:10","pubTimestamp":1741630242,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时10分，Adc Therapeutics Sa股票出现异动，股价急速跳水5.16%。截至发稿，该股报1.75美元/股，成交量14.2555万股，换手率0.15%，振幅4.35%。Adc Therapeutics Sa股票所在的生物技术行业中，整体涨幅为0.69%。Adc Therapeutics Sa公司简介：ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102104298a2d3e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102104298a2d3e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","ADCT","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517192786","title":"Adc Therapeutics Sa盘中异动 下午盘急速拉升5.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517192786","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517192786?lang=zh_cn&edition=full","pubTime":"2025-03-07 03:49","pubTimestamp":1741290558,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日03时49分，Adc Therapeutics Sa股票出现异动，股价快速上涨5.62%。Adc Therapeutics Sa股票所在的生物技术行业中，整体跌幅为0.45%。其相关个股中，Plus Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Aeon Biopharma, Inc.涨幅较大，Aeon Biopharma, Inc.、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为5163.60%、4474.05%、264.87%，振幅较大的相关个股有Plus Therapeutics, Inc.、Surrozen Inc C/Wts 01/08/2031 、Tonix Pharmaceuticals Holding Corp.，振幅分别为172.51%、127.10%、71.44%。Adc Therapeutics Sa公司简介：ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307034918989eeb10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307034918989eeb10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","ADCT","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517941825","title":"Adc Therapeutics Sa盘中异动 股价大跌5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517941825","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517941825?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:17","pubTimestamp":1741191430,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时17分，Adc Therapeutics Sa股票出现异动，股价大幅跳水5.59%。Adc Therapeutics Sa股票所在的生物技术行业中，整体涨幅为1.22%。其相关个股中，Chimerix, Inc.、Nutriband Inc C/Wts 、Oculis Holding Ag C/Wts 06/03/2028 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为895.85%、291.89%、278.41%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 ，振幅分别为82.59%、54.27%、41.26%。Adc Therapeutics Sa公司简介：ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306001711abe9d15d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306001711abe9d15d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADCT","LENZ","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516163203","title":"Adc Therapeutics Sa盘中异动 急速下挫5.68%报1.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516163203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516163203?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:58","pubTimestamp":1741013906,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时58分，Adc Therapeutics Sa股票出现波动，股价大幅下跌5.68%。截至发稿，该股报1.66美元/股，成交量1.9903万股，换手率0.02%，振幅4.64%。Adc Therapeutics Sa股票所在的生物技术行业中，整体涨幅为0.00%。Adc Therapeutics Sa公司简介：ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225826a25d4829&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225826a25d4829&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","ADCT","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514863067","title":"Adc Therapeutics Sa盘中异动 快速上涨5.13%报1.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514863067","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514863067?lang=zh_cn&edition=full","pubTime":"2025-02-27 01:17","pubTimestamp":1740590229,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日01时17分，Adc Therapeutics Sa股票出现波动，股价快速拉升5.13%。截至发稿，该股报1.64美元/股，成交量7.8446万股，换手率0.08%，振幅4.81%。Adc Therapeutics Sa股票所在的生物技术行业中，整体跌幅为0.03%。Adc Therapeutics Sa公司简介：ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227011710abde11c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227011710abde11c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADCT","BK4139","BK4505","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514201112","title":"Adc Therapeutics Sa盘中异动 早盘股价大跌5.00%报1.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514201112","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514201112?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:27","pubTimestamp":1740500854,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时27分，Adc Therapeutics Sa股票出现异动，股价快速跳水5.00%。截至发稿，该股报1.52美元/股，成交量7.8271万股，换手率0.08%，振幅4.32%。Adc Therapeutics Sa股票所在的生物技术行业中，整体涨幅为0.35%。Adc Therapeutics Sa公司简介：ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226002734a253a15b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226002734a253a15b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","ADCT","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513729697","title":"Stephens & Co.：维持ADC Therapeutics(ADCT.US)评级，由增持调整至增持评级, 目标价由6.00美元调整至8.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513729697","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513729697?lang=zh_cn&edition=full","pubTime":"2025-02-24 21:22","pubTimestamp":1740403325,"startTime":"0","endTime":"0","summary":"Stephens & Co.：维持ADC Therapeutics(ADCT.US)评级，由增持调整至增持评级, 目标价由6.00美元调整至8.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24212248352457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ADC","LENZ","ADCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512166105","title":"Adc Therapeutics Sa盘中异动 大幅拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512166105","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512166105?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:45","pubTimestamp":1739889906,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时45分，Adc Therapeutics Sa股票出现波动，股价大幅拉升5.00%。Adc Therapeutics Sa股票所在的生物技术行业中，整体涨幅为0.73%。其相关个股中，Solid Biosciences Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为305.91%、111.39%、89.11%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Jasper Therapeutics Inc C/Wts 24/09/2026 、Conduit Pharmaceuticals Inc.，振幅分别为41.79%、34.04%、26.83%。Adc Therapeutics Sa公司简介：ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224506a24aafc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224506a24aafc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ADCT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adctherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1495},{"period":"1month","weight":-0.016},{"period":"3month","weight":-0.6339},{"period":"6month","weight":-0.6917},{"period":"1year","weight":-0.5816},{"period":"ytd","weight":-0.6516}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":0.0311},{"period":"3month","weight":0.0325},{"period":"6month","weight":0.1331},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ADC Therapeutics SA于2011年6月6日根据瑞士法律注册成立。该公司是一家完全整合的商业阶段生物技术公司，通过下一代靶向抗体药物偶联物帮助改善癌症患者的生活。该公司的旗舰产品ZYNLONTA（loncastuximab tesirine或Lonca）于2021年4月23日获得FDA的加速批准，并在此后不久在美国上市，用于治疗经过两个或两个以上系统治疗的复发或难治性大B细胞淋巴瘤成人患者，包括未另行说明的弥漫性大B细胞淋巴瘤、由低级别淋巴瘤引起的DLBCL，以及高级别B细胞淋巴瘤。该公司的目标是将ZYNLONTA确立为三线+ DLBCL护理标准，同时探索ZYNLONTA在早期治疗和组合中的应用，以扩大市场机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.12605},{"month":2,"riseRate":0.666667,"avgChangeRate":0.069601},{"month":3,"riseRate":0,"avgChangeRate":-0.169217},{"month":4,"riseRate":0.5,"avgChangeRate":-0.032368},{"month":5,"riseRate":0.333333,"avgChangeRate":0.085466},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.061138},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.065227},{"month":8,"riseRate":0.428571,"avgChangeRate":0.031531},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.079772},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.058531},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.016563},{"month":12,"riseRate":0.333333,"avgChangeRate":0.076305}],"exchange":"NYSE","name":"ADC Therapeutics SA","nameEN":"ADC Therapeutics SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADC Therapeutics SA(ADCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ADC Therapeutics SA(ADCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ADC Therapeutics SA,ADCT,ADC Therapeutics SA股票,ADC Therapeutics SA股票老虎,ADC Therapeutics SA股票老虎国际,ADC Therapeutics SA行情,ADC Therapeutics SA股票行情,ADC Therapeutics SA股价,ADC Therapeutics SA股市,ADC Therapeutics SA股票价格,ADC Therapeutics SA股票交易,ADC Therapeutics SA股票购买,ADC Therapeutics SA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADC Therapeutics SA(ADCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ADC Therapeutics SA(ADCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}